About osteoporosis
Osteoporosis, or porous bone, is a disease characterized by low bone density and structural deterioration of bone tissue, leading to fragile bones. As bones becomes fragile, risk of fracture increases. Osteoporosis primarily affects women, but can also affect men. In women, bone loss occurs rapidly in the first few years after menopause and continues through the postmenopausal stage. Osteoporosis progresses when bone resorption occurs too quickly or when replacement is too slow. Risk factors for osteoporosis include gender, age, low body weight, ethnicity, and family history. Some of the risk factors that can be manipulated include sex hormones, medication use, intake of calcium and vitamins, alcohol intake, and smoking.
Technavio's analysts forecast the global osteoporosis drugs market to grow at a CAGR of 4.14 percent over the period 2014-2019.
Covered in this report
This report covers the present scenario and the growth prospects of the global osteoporosis drugs market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various osteoporosis drugs, including products with approved labeling and generic versions.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the global osteoporosis drugs market. The vendor landscape section includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market. In addition, clinical stage pipeline molecules developed for the treatment of osteoporosis are discussed.
Technavio's report, Global Osteoporosis Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC; it also covers the global osteoporosis drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key vendors
• Amgen
• Eli Lilly
• Merck
• Novartis
Other Prominent Vendors
• Abiogen Pharma
• Deltanoid Pharmaceuticals
• F. Hoffmann La Roche
• GlaxoSmithKline
• IMMD
• Ligand Pharmaceuticals
• NPS Pharma
• Pantarhei Bioscience
• Pfizer
• PhytoHealth
• Radius Health
• UPSHER-SMITH LABORATORIES
• Zosano Pharma
Market driver
• Increase in aging population
• For a full, detailed list, view our report
Market Challenge
• Multiple expiries of patents
• For a full, detailed list, view our report
Market trend
• Increase in awareness about bone health
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview
06.1 Understanding Osteoporosis
06.2 Epidemiology and Demography
06.3 Risk Factors
06.4 Symptoms
06.5 Diagnosis
06.6 Treatment
07. Key Development in Osteoporosis Therapy
08. Market Landscape
08.1 Market Overview
08.1.1 Market Size and Forecast
08.2 Osteoporosis Drugs Market in US
08.2.1 Market Size and Forecast
08.3 Osteoporosis Drugs Market in Europe
08.3.1 Market Size and Forecast
08.4 Five Forces Analysis
09. Market Segmentation by Therapeutic Class
09.1 Global Osteoporosis Drugs Market by Therapeutic Class 2014-2019
09.2 Antiresorptive Medications
09.3 Anabolic Medications
10. Market Segmentation by Line of Therapy
10.1 Global Osteoporosis Drugs Market by Line of Therapy
11. Pipeline Assessment
11.1 Key Information about Pipeline Candidates
12. Geographical Segmentation
12.1 Global Osteoporosis Drugs Market by Geographical Segmentation 2014-2019
12.2 Osteoporosis Drugs Market in Americas
12.2.1 Market Size and Forecast
12.3 Osteoporosis Drugs Market in EMEA
12.3.1 Market Size and Forecast
12.4 Osteoporosis Drugs Market in APAC
12.4.1 Market Size and Forecast
13. Buying Criteria
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.1.3 Vendor Ranking 2014
20.1.4 Competitive Assessment of Major Drugs
20.1.5 Amgen
20.1.6 Eli Lilly
20.1.7 Merck
20.1.8 Novartis
20.2 Other Prominent Vendors
21. Key Vendor Analysis
21.1 Amgen
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation by Revenue 2013
21.1.4 Product Portfolio by Revenue 2013
21.1.5 Business Segmentation by Revenue 2012 and 2013
21.1.6 Geographical Segmentation by Revenue 2013
21.1.7 Business Strategy
21.1.8 Recent Developments
21.1.9 SWOT Analysis
21.2 Eli Lilly
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Business Segmentation by Revenue
21.2.4 Sales by Geography
21.2.5 Business Strategy
21.2.6 Key Information
21.2.7 SWOT Analysis
21.3 Merck & Co. Inc.
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation by Revenue 2013
21.3.4 Business Segmentation by Revenue 2012 and 2013
21.3.5 Sales by Geography
21.3.6 Business Strategy
21.3.7 Key Developments
21.3.8 SWOT Analysis
21.4 Novartis AG
21.4.1 Key Facts
21.4.2 Business Description
21.4.3 Business Segmentation
21.4.4 Revenue by Business Segmentation
21.4.5 Revenue Comparison 2012 and 2013
21.4.6 Sales by Geography
21.4.7 Business Strategy
21.4.8 Key Developments
21.4.9 SWOT Analysis
22. Other Reports in this Series
List Of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Interpretation of BMD Results
Exhibit 3: Global Osteoporosis Drugs Market 2014-2019 ($ billion)
Exhibit 4: Osteoporosis Drugs Market in US 2014-2019 ($ billion)
Exhibit 5: Osteoporosis Drugs Market in Europe 2014-2019 ($ billion)
Exhibit 6: Segmentation of Global Osteoporosis Drugs Market by Geography 2014
Exhibit 7: Segmentation of Global Osteoporosis Drugs Market by Geography 2019
Exhibit 8: Osteoporosis Drugs Market in Americas 2014-2019 ($ billion)
Exhibit 9: Osteoporosis Drugs Market in EMEA 2014-2019 ($ billion)
Exhibit 10: Osteoporosis Drugs Market in APAC 2014-2019 ($ billion)
Exhibit 11: Segmentation of Global Osteoporosis Drugs Market by Geography 2014-2019
Exhibit 12: Revenue Comparison of Top Osteoporosis Drugs for First Three Quarters 2014 ($ million)
Exhibit 13: YoY Growth Rate and Global Revenue of Prolia 2010-2013 ($ million)
Exhibit 14: Revenue of Prolia by Country/Region 2010-2013 ($ million)
Exhibit 15: YoY Growth Rate and Global Revenue of Evista 2010-2013 ($ million)
Exhibit 16: Revenue of Evista by Country/Region 2010-2013 ($ million)
Exhibit 17: YoY Growth Rate and Global Revenue of Forteo 2010-2013 ($ million)
Exhibit 18: Revenue of Forteo by Country/Region 2010-2013 ($ million)
Exhibit 19: YoY Growth Rate and Global Revenue of Fosamax 2011-2014 ($ million)
Exhibit 20: YoY Growth Rate and Global Revenue of Reclast/Aclasta 2010-2013 ($ million
Exhibit 21: Revenue of Reclast/Aclasta by Country/Region 2010-2012 ($ million)
Exhibit 22: Amgen: Business Segmentation by Revenue 2013
Exhibit 23: Amgen: Product Portfolio by Revenue 2013
Exhibit 24: Amgen: Business Segmentation by Revenue 2012 and 2013 ($ billion)
Exhibit 25: Amgen: Geographical Segmentation by Revenue 2013
Exhibit 26: Eli Lilly: Business Segmentation by Revenue 2013
Exhibit 27: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 ($ million)
Exhibit 28: Eli Lilly: Sales by Geography 2013
Exhibit 29: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 30: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 ($ billion)
Exhibit 31: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 32: Novartis AG: Business Segmentation
Exhibit 33: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 34: Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ million)
Exhibit 35: Novartis AG: Revenue by Geographical Segmentation 2013
